An oncolytic herpes simplex virus vector, G47Δ, synergizes with paclitaxel in the treatment of breast cancer

Oncology Reports

Volumn 29, Issue 6, 2013, Pages 2355-2361

  Zeng, Wei Gen ^a   Li, Jun Jie ^b   Hu, Pan ^a   Lei, Lan ^a   Wang, Jia Ni ^a   Liu, Ren Bin ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b SICHUAN CANCER HOSPITAL   (China)

Author keywords

Breast cancer; Combination therapy; Herpes simplex virus; Oncolytic virus; Paclitaxel

Indexed keywords

LIPOCORTIN 5; ONCOLYTIC HERPES SIMPLEX VIRUS VECTOR G47DELTA; PACLITAXEL; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BODY WEIGHT; BREAST CANCER; CANCER CELL; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; FEMALE; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MITOSIS INHIBITION; MORBIDITY; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIORITY JOURNAL; TUMOR VOLUME; VIRUS REPLICATION;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; CELL CYCLE CHECKPOINTS; CELL SURVIVAL; CERCOPITHECUS AETHIOPS; COMBINED MODALITY THERAPY; FEMALE; GENETIC VECTORS; HUMANS; MCF-7 CELLS; MICE; MICE, INBRED BALB C; MICE, NUDE; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PACLITAXEL; SIMPLEXVIRUS; TUMOR BURDEN; VERO CELLS; VIRUS REPLICATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84876252696     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2359     Document Type: Article

References (24)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Perou CM, Sørlie T, Eisen MB, et al: Molecular portraits of human breast tumours. Nature 406: 747-752, 2000.
3. Sørlie T, Perou CM, Tibshirani R, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98: 10869-10874, 2001. (Pubitemid 32878711)
4. Sotiriou C, Neo SY, McShane LM, et al: Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA 100: 10393-10398, 2003. (Pubitemid 37071889)
5. Lim E and Winer EP: Adjuvant chemotherapy in luminal breast cancers. Breast 20 (Suppl 3): S128-S131, 2011.
6. Paridaens R, Biganzoli L, Bruning P, et al: Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over. J Clin Oncol 18: 724-733, 2000. (Pubitemid 30106602)
7. Sledge GW, Neuberg D, Bernardo P, Ingle JN, Martino S, Rowinsky EK and Wood WC: Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 21: 588-592, 2003. (Pubitemid 46621890)
8. Ghersi D, Wilcken N and Simes RJ: A systematic review of taxane-containing regimens for metastatic breast cancer. Br J Cancer 93: 293-301, 2005. (Pubitemid 43080031)
9. Henderson IC, Berry DA, Demetri GD, et al: Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21: 976-983, 2003. (Pubitemid 46594124)
10. Varghese S and Rabkin SD: Oncolytic herpes simplex virus vectors for cancer virotherapy. Cancer Gene Ther 9: 967-978, 2002. (Pubitemid 35462560)
11. Todo T, Martuza RL, Rabkin SD and Johnson PA: Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc Natl Acad Sci USA 98: 6396-6401, 2001. (Pubitemid 32488248)
12. Fukuhara H, Martuza RL, Rabkin SD, Ito Y and Todo T: Oncolytic herpes simplex virus vector g47delta in combination with androgen ablation for the treatment of human prostate adenocarcinoma. Clin Cancer Res 11: 7886-7890, 2005. (Pubitemid 41611635)
13. Wang JN, Hu P, Zeng MS and Liu RB: Anti-tumor effect of oncolytic herpes simplex virus G47delta on human nasopharyngeal carcinoma. Chin J Cancer 30: 831-841, 2011.
14. Liu R, Varghese S and Rabkin SD: Oncolytic herpes simplex virus vector therapy of breast cancer in C3(1)/SV40 T-antigen transgenic mice. Cancer Res 65: 1532-1540, 2005. (Pubitemid 40270182)
15. Petrowsky H, Roberts GD, Kooby DA, et al: Functional interaction between fluorodeoxyuridine-induced cellular alterations and replication of a ribonucleotide reductase-negative herpes simplex virus. J Virol 75: 7050-7058, 2001. (Pubitemid 32641592)
16. Eisenberg DP, Adusumilli PS, Hendershott KJ, et al: 5-fluorouracil and gemcitabine potentiate the efficacy of oncolytic herpes viral gene therapy in the treatment of pancreatic cancer. J Gastrointest Surg 9: 1068-1077, 2005.
17. Bennett JJ, Adusumilli P, Petrowsky H, et al: Up-regulation of GADD34 mediates the synergistic anticancer activity of mitomycin C and a gamma134.5 deleted oncolytic herpes virus (G207). FASEB J 18: 1001-1003, 2004. (Pubitemid 39561505)
18. Aghi M, Rabkin S and Martuza RL: Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication. J Natl Cancer Inst 98: 38-50, 2006. (Pubitemid 43057091)
19. Liu R, Martuza RL and Rabkin SD: Intracarotid delivery of oncolytic HSV vector G47Delta to metastatic breast cancer in the brain. Gene Ther 12: 647-654, 2005. (Pubitemid 40561503)
20. Wang J, Hu P, Zeng M, Rabkin SD and Liu R: Oncolytic herpes simplex virus treatment of metastatic breast cancer. Int J Oncol 40: 757-763, 2012.
21. Gonzalez-Angulo AM, Morales-Vasquez F and Hortobagyi GN: Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 608: 1-22, 2007.
22. Elliott G and O'Hare P: Herpes simplex virus type 1 tegument protein VP22 induces the stabilization and hyperacetylation of microtubules. J Virol 72: 6448-6455, 1998. (Pubitemid 28323958)
23. Kim WY, Woo SU, Seo JH, Son GS, Lee JB and Bae JW: Toxicities, dose reduction and delay of docetaxel and paclitaxel chemotherapy in breast cancer without distant metastases. J Cancer Res Ther 7: 412-415, 2011.
24. Loibl S, Skacel T, Nekljudova V, et al: Evaluating the impact of Relative Total Dose Intensity (RTDI) on patients' short and long-term outcome in taxane- and anthracycline-based chemotherapy of metastatic breast cancer- a pooled analysis. BMC Cancer 12: 121-131, 2011.